The announcement was widely interpreted as a signal that the FDA under the new administration would take a more permissive stance toward peptide compounding than the 2023 Pharmacy Compounding Advisory Committee position, which had placed BPC-157 firmly in Category 2 (substances the FDA had concerns about for compounding use)
De Groot AS, Roberts BJ, Mattei A, Lelias S, Boyle C, Martin WD
Effects of Arachidonic Acid, Prostaglandins, Retinol, Retinoic Acid and Cholecalciferol on Xenobiotic Oxidations Catalysed by Human Cytochrome P450 Enzymes
While BPC-157 and TB-500 focus primarily on acute tissue repair signaling, GHK-Cu acts as a broad tissue remodeling agent that enhances collagen synthesis, reduces inflammation, and supports the long-term structural quality of healed tissue
Multiple orders in and the consistency hasn't slipped once
It serves as a cofactor for the enzyme methionine synthase, which converts homocysteine to methionine